biote Corp.
Close on Oct 19, 2026
- Market cap
- $30.92M
- P/E (TTM)
- 10.8
- Dividend yield
- –
Earnings
Next report expected Nov 4, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 5, 2026 | During market hours | $44.20M | $-0.23 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 6, 2026 | During market hours | $44.90M | $0.06 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 11, 2026 | During market hours | $46.40M | $0.06 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 5, 2025 | During market hours | $48.00M | $0.22 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 6, 2025 | During market hours | $48.90M | $0.10 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 7, 2025 | During market hours | $49.00M | $0.37 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 12, 2025 | During market hours | $49.80M | $0.10 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | During market hours | $51.40M | $0.33 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | During market hours | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 7, 2024 | During market hours | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Jan 17, 2024 | During market hours | – | – | – |
Company guidance
Outlook given with results on Aug 5, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Adjusted EBITDAnon-GAAP | 2026 | $25.00M | Lowered |
| Revenue | 2026 | $175.00M | Lowered |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements biote filed with the SEC
Biote Reports Second Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Biote Names Bob Peterson, Current Chief Financial and Chief Business Officer, as Interim
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Biote Reports First Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
2 Transforming Healthy Aging Forward-Looking Statements Forward-Looking
Regulation FD disclosure · EX-99.1 to Form 8-K
Biote Reports Fourth Quarter and Full Year 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Biote Reports Third Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Biote Reports Second Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Biote Names Rich Barrera to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Biote Reports First Quarter 2025 Financial Results
Results of operations · Exit or restructuring costs · EX-99.1 to Form 8-K
Biote Reports Fourth Quarter and Full Year 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Biote Announces CEO Retirement and Succession Plan
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Biote Reports Third Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Biote Reports Second Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Biote Announces $60 Million Agreement to Repurchase 8.3 Million Shares and Cancel Approximately 4.0
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Biote Reports First Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Biote Announces Definitive Settlement with Founder
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Biote Reports Fourth Quarter and Full Year 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Biote Announces Agreement to Resolve Litigation and Repurchase All of
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Biote Announces $20 Million Share Repurchase Authorization
Other events · EX-99.1 to Form 8-K
Biote Provides Preliminary 2023 Results and Initial 2024 Guidance
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Biote to Purchase Asteria Health
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Biote Names Robert Peterson as Chief
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Biote Reports Third Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Biote Reports Second Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Biote Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Warrants
Material agreement · Shareholder vote results · Other events · EX-99.1 to Form 8-K
Biote Reports First Quarter 2023 Financial Results
Results of operations · Other events · EX-99.1 to Form 8-K
Biote Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants
Results of operations · Other events · EX-99.2 to Form 8-K
Biote Reports Fourth Quarter and Full Year 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Biote Reports Third Quarter Financial Results
Results of operations · EX-99.1 to Form 8-K
Biote Appoints Debby Morris to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Biote Releases Updated Corporate Presentation for October 2022
Regulation FD disclosure · EX-99.1 to Form 8-K
Biote Announces Approval to Relist on The Nasdaq Stock Market
Regulation FD disclosure · EX-99.1 to Form 8-K
Biote Appoints Samar Kamdar as Chief Financial Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Biote Issues Correction to Second Quarter Operating Loss and Net Income
Results of operations · EX-99.1 to Form 8-K/A
Second Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Unaudited Quarterly Financial Results for 2021
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Confidential Material – Do Not Distribute
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Biote Debuts as Publicly Traded Company Focused on Transforming Hormone Optimization Industry
Listing notice · Regulation FD disclosure · EX-99.1 to Form 8-K